What question did this study set out to answer?

Evaluate the efficiency of PET-CT adapted therapy after ABVD treatment in classic Hodgkin lymphoma.

Long‐term follow‐up of PET / CT ‐adapted therapy after three cycles of ABVD for all stages of classic Hodgkin lymphoma: Results of the GATLA LH ‐05 trial

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates PET-CT guided therapy in classic Hodgkin lymphoma, indicating effective disease control and reduced treatment exposure.

Evaluate the efficiency of PET-CT adapted therapy after ABVD treatment in classic Hodgkin lymphoma.
Prospective, non-randomized trial with 563 patients
Patients received three cycles of ABVD followed by PET-CT assessment
Treatment decisions based on PET3 Deauville scores
5-year progression-free survival (PFS) was 78.9% (95% CI 75.5–82.6)
10-year overall survival (OS) was 93.7% (95% CI 91.5–96.0)
PET3 was the strongest predictor of PFS, with all PET3-negative patients achieving 10-year PFS of 84.4%

Pavlovsky et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates PET-CT guided therapy in classic Hodgkin lymphoma, indicating effective disease control and reduced treatment exposure.